

April 25, 2002

Mr. Edward F. Jacoby, Jr., Chairman  
New York State Disaster Preparedness  
Commission  
1220 Washington Avenue  
Building 22, Suite 101  
Albany, New York 12226-2251

Dear Mr. Jacoby:

I am responding to your letter of March 22, 2002, requesting the Nuclear Regulatory Commission's assistance and support in gaining FDA approval for doses of potassium iodide in other than the 130 mg size currently approved.

The staff has reviewed the issues you raised and has forwarded your letter to the Food and Drug Administration (FDA) for resolution. The FDA is the definitive medical authority in the United States on the use of potassium iodide. As such, the FDA is the appropriate agency to respond to your concerns.

The FDA has agreed to respond directly to you. If you have any questions, please contact Dr. David Orloff, Director, Division of Metabolic and Endocrine Drug Products, Office of New Drugs, Center for Drug Evaluation and Research at the FDA, at 301-827-6430.

Sincerely,

*/RA/*

Richard A. Meserve